Idera Pharmaceuticals, Inc.

365 articles with Idera Pharmaceuticals, Inc.

• 

  ASCO 2018: Results Keep Rolling In

  6/4/2018

  There’s plenty of news coming out of the American Society of Clinical Oncology (ASCO) Annual Meeting behind held in Chicago. Here’s a look at a few more of the top stories.

• Idera Pharmaceuticals Increases Operational Efficiency of Global Oncology Program with Medidata Clinical Cloud

  5/1/2018

  Medidata’s Solutions to Accelerate Studies, Improve Data Quality, and Drive Greater Patient Enrollment

• BioCryst Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with Idera Pharmaceuticals

  4/2/2018

  BioCryst Mails Letter to Stockholders Highlighting Compelling Upside Opportunity

• 

  Idera, Biocryst Tie the Knot and Transform Into a Rare Disease Pharma

  1/22/2018

  The combined company will be renamed upon closing and will be led by Vincent Milano, CEO of Idera, who will also serve as a member of the Board.

• Idera Pharmaceuticals Provides 2018 Update and Outlook

  1/5/2018

  Company to present at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 11:00 AM PT/2:00 PM ET.

• 

  2 Biotechs Under $5 Bucks Investors Should Put on Their Watchlists

  12/4/2017

  Why investors may want to keep an eye on Idera Pharmaceuticals and Ekso Bionics.

• U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma

  11/29/2017

  FDA’s Fast Track program is designed to expedite the development and review of drugs and biologics to treat serious or life-threatening conditions.

• Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC)

  11/9/2017

  These data will be presented at 4:45 P.M. E.T. on Saturday, November 11th.

• Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update

  11/7/2017

  Net loss applicable to common stockholders for the three months ended September 30, 2017 was $14.5 million, or $0.10 per basic and diluted share, compared to a net loss applicable to common stockholders of $12.9 million.

• Idera Pharmaceuticals Announces Pricing of Public Offering of Common Stock

  10/26/2017

  The Company has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock

• Idera Pharmaceuticals Provides Corporate Governance Update

  10/25/2017

  Youssef El Zein, Managing Partner of Pillar Invest Corporation has elected to step down from the company’s Board of Directors, effective immediately.

• Idera Pharmaceuticals Announces Proposed Public Offering of Common Stock

  10/25/2017

  The company intends to offer and sell up to $60 million of shares of its common stock in an underwritten public offering. In connection with this offering.

• Idera Pharma Presents Positive Phase I Data For Intratumoral IMO-2125 In Combination With Ipilimumab Demonstrating An Overall Response Rate (ORR) Of 44% In Melanoma Patients Refractory To Anti-PD1 Therapy

  9/11/2017

• Idera Pharma Presents Pre-Clinical Data From IMO-2125 Treatment In Combination With Ipilimumab That Demonstrates Induction Of Durable Anti-Tumor Responses Associated With Tumor-Specific Memory

  9/8/2017

• Idera Pharma To Host Investor Conference Call On Monday, September 11, 2017 At 9:00 A.M. E.T.

  9/7/2017

• Idera Pharma Reports Second Quarter 2017 Financial Results And Provides Corporate Update

  8/8/2017

• Idera Pharma Reports First Quarter 2017 Financial Results And Provides Corporate Update

  5/5/2017

• Idera Pharma Founder and Research Head to Retire

  4/19/2017

• Idera Pharma Advances Investigational Treatment—Intratumoral IMO-2125 In Combination With Ipilimumab - For Unmet Need In Anti-PD-1 Refractory Metastatic Melanoma

  4/11/2017

• Analyst Calls For Exponential Upside For Idera Pharma

  3/27/2017